Friday, 5 June 2020

Lactose Intolerance Treatment Market 2020 Global Market Trends, Share, Size, Growth, Opportunity and Forecast to 2025

Market scenario:
The Global Lactose Intolerance Treatment Market is expected to register a CAGR of 7.10% and reach USD 41,054.4 Million by 2025. Lactose Intolerance treatment is a digestive problem with an impaired ability to digest lactose. Factors such as rising cases of gastrointestinal disorders, increasing awareness about Lactose Intolerance treatment and related complications, and increased prevalence of Lactose Intolerance treatment are the driving forces for the market. However, side-effects associated with supplements is projected to restraint the market during the forecast period (2019-2025).
Market Dynamics
Lactose Intolerance treatment is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, abdominal pains, and others. There are four types of lactose intolerance, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due to irritable bowel syndrome (IBS), gastroenteritis, Crohn disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study suggested by the Journal of Health, Population, and Nutrition in 2017, the prevalence of Lactose Intolerance treatment was significantly higher in IBS-D patients than in healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration. It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
Segmentation
The global Lactose Intolerance treatment market has been segmented by type of lactose intolerance, treatment, form, and end user. The market, based on type, has been bifurcated into primary lactose intolerance, secondary lactose intolerance, and congenital/developmental lactose intolerance. Based on form, the Lactose Intolerance treatment market has been segregated into food supplements, enzyme lactase supplements, probiotics, and others (combination products and prebiotics). By form, the global Lactose Intolerance treatment market has been segmented into tablets/capsule, powder, and liquid. On the basis of end-user, the market has been divided into home care and hospitals & clinics. 
The food supplements segment, by treatment is estimated to hold a share of 70.4% in the market.
Regional Analysis
The global Lactose Intolerance treatment market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Europe held the major market share of 42.0% in 2018. The dairy consumption in Western Europe is good in comparison to other regions of Europe and has a high per-capita consumption rate throughout the region. The Americas held the second largest market share of 28% in 2018. It is further segmented into North and Latin America. The consumption of dairy products is also distinct and variable in the Americas. Latin America, for example, is one of the fastest-growing dairy markets in the world. Consumers in this region are looking for more convenient ways to shop. They seek to purchase products from a single location or store, and it is one of the main drivers of hypermarkets and supermarkets in Latin America. Asia-Pacific is the third-largest region and held the market share of 20.0% in 2018. In terms of value, it has the largest dairy consumption, but it has the lowest per capita income spent on dairy products as it is still developing better infrastructure for the distribution of chilled dairy products. The Middle East and Africa is highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world.
Key Players
The prominent players in the global are Abbott Laboratories, Inc. (US), Nestle (Switzerland), Cargill, Incorporated (US), Dean Foods (US), Johnson & Johnson, Inc. (US), and Novozyme, (Denmark) are some of the major players in the market.
Some of the key strategies followed by players operating in the global Lactose Intolerance treatmentmarket were innovation, product development, and acquisition & mergers.
  • In March-2018, Nestlé completed its acquisition of Atrium Innovations Inc., a global leader in nutritional health products. This acquisition supports Nestlé’s pursuit of growth opportunities in consumer healthcare to complement the company’s focus on its high-growth food and beverage categories
  • In April-2017, Abbott introduced science-based nutrition drinks to help patients have a better recovery from surgery. New Ensure Surgery Immunonutrition Shake and Ensure Pre-Surgery Clear Nutrition Drink is designed for hospitals implementing surgical guidelines for enhancing patient recovery. These drinks are also lactose-free.
  • In May,2016- Dean Foods launched a new DairyPure brand, lactose free milk to its line of dairy products. DairyPure lactose-free milk delivers real dairy nutrition and delicious taste. Also, it is 100% lactose-free, making it easy to digest for those with lactose sensitivities.
Posted by at No comments:

2020 Latest Study explores the Medical Smart Textile Market Witness Highest Growth in near future by 2027

Market Insights:
The Global Medical Smart Textile Market is expected to register a CAGR of 7.51% to reach 2,105.32 Million by 2027. Medical smart textile is a new field of research and is most widely used in the healthcare sector. Sensors are integrated into the textiles, in continuous contact with the human body, and could capture physiological changes occurring within the body. The demand for medical smart textiles is increasing due to the rising burden of diseases, evolving methods of diagnosis, and extensive use of wearable medical devices. These factors are expected to fuel the growth of the global medical smart textile market. However, the high cost of smart textiles is anticipated to hamper the market growth.
Key Players
The global medical smart textile market overview by Market research Future contains The top prominent players like Schoeller Switzerland, Vista Medical Ltd, Sensoria Inc., Gentherm, Siren, Pireta, AiQ Smart Clothing, Camira Fabrics, Carre Technologies Inc, and 3teks.
Some of the key strategies followed by players operating in the global medical smart textile market were innovation, product development, and acquisition & mergers.
  • In February 2019, Gentherm signed a partnership agreement with ThermoAnalytics, Inc., a leading thermal modeling software development firm for the advancement of human thermal comfort predictions.
  • In June 2019, Pireta developed a unique process that adds conductive metallic pattern directly into textile clothing without changing the fabric feel. These wearable smart garments and e-textile enabled physicians to diagnose diseases in their early stages and provide better treatment options. The launch of this device would help the company to increase its revenue in the future.
  • In July 2019, Camira Fabric acquired Luna Textiles, a US-based company that manufactures fabric for healthcare, hospitality, and other lounge seating purposes. This acquisition helped Camira Fabric to increase its revenue.
Market Dynamics
The rising burden of diseases is expected to fuel the growth of the global medical smart textile market during the forecast period. According to the Global Burden of Disease Study in 2017, from 1990 to 2017, the leading causes of premature deaths were neonatal disorders, ischemic heart disease, lower respiratory infections, diarrhea, chronic obstructive pulmonary disease (COPD), and strokes. These diseases accounted for more than 1 million deaths worldwide in 2017. Additionally, the Global Burden of Disease Study in 2017, stated that there was a change in the mortality rate due to excess drug-resistant tuberculosis from 2007 to 2017.
Segmentation
The global medical smart textile market has been segmented by technology, application, and end user. The market, based on technology, has been divided into wearable technology, textile sensors, and others. Based on application, the medical smart textile market has been segregated into bio-monitoring, surgery, therapy, and wellness and others. The global medical smart textile market, based on end user, has been bifurcated into hospitals and clinics and others. The hospitals and clinics held a share of 67.3% in 2018.
Regional Market Summary
The global medical smart textile market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global medical smart textile market. The growth in this region can be attributed to the extensive use of medical devices. Moreover, applications in medical engineering for monitoring vital health indicators help in maximizing the growth of the market in this region. Europe held a substantial share in the global medical smart textile market. This can be attributed to the rising government expenditure to promote the healthcare sector in the region. For instance, according to Eurostat, in 2016, healthcare expenditure per person was EUR 5,000 or higher in three EU member states that are Luxembourg (EUR 5,600), Sweden (EUR 5,100) and Denmark (EUR 5,000), as the per-person healthcare expenditure is very high in Europe and is continuously growing. Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the extensive demand for advanced medical devices and increasing applications of technology in the early diagnosis of diseases fueling the growth of the medical smart textile market in the region. The medical smart textile market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2027. The Middle East would lead the market growth in this region. Increasing awareness about medical smart textiles is expected to drive market growth during the assessment period.
Posted by at No comments:

Global Implantable Cardioverter Defibrillator (ICD) Market 2020 by manufacturers, Demand, application, and region 2025

Market Synopsis
The Global Implantable Cardioverter Defibrillator (ICD) Market: Increasing prevalence of cardiovascular diseases, growing aging population, and changing lifestyles are projected to boost the market from USD 6,952.2 Million in 2018 to 10,425.96 Million by 2025 at a CAGR of 5.96%.
Top Key Players
Top Implantable Cardioverter Defibrillator (ICD) Market Manufacturers in the Global market are Abbott Laboratories (US), BIOTRONIK (Germany), Boston Scientific Corporation (US), Medtronic (Ireland), MicroPort Scientific Corporation (China), Koninklijke Philips N.V. (Netherlands), Nihon Kohden Corporation (Japan), Progetti Srl (Italy), Fukuda Denshi Co., Ltd (Japan), Getinge (Sweden), ZOLL Medical Corporation (US), etc.
Market Highlights
According to MRFR analysis, the global implantable cardioverter defibrillator (ICD) market is expected to register a CAGR of 5.96% during the forecast period of 2019 to 2025. Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. Factors such as the growing aging population, changing lifestyles such as smoking and alcohol consumption, and the increase in demand for cardiac implants are responsible for the increasing prevalence of cardiac arrhythmias globally. This is likely to fuel the growth of the ICD market during the forecast period. In addition to this, improving efficacy of ICDs for the treatment of cardiac diseases over a period will also fuel the market. According to the American Heart Association, approximately 1.5 million cases of myocardial infarction occur annually, and the incidence rate is approximately 600 cases per 100,000 people in the US. According to the American College of Cardiology Foundation, sudden cardiac arrest (SCA) is also one of the leading causes of death worldwide and is responsible for 250,000 to 450,000 deaths per year in the US. Also, coronary artery disease is a major risk factor for sudden cardiac arrest (SCA).
The global implantable cardioverter defibrillator (ICD) market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen their market positions. For instance, in May 2019, the US Food and Drug Administration (FDA) has approved Boston Scientific's Emblem S-ICD that is used in the treatment of cardiovascular diseases. Through this approval, Boston Scientific focuses on strengthening its position in the US ICD market. Medtronic is developing Extravascular (EV) ICD system, an innovative subcutaneous ICD that is designed to terminate arrhythmias, post-shock pacing to protect from sudden cardiac arrest, and temporary back-up bradycardia pacing.
Segmentation
By Type
  • Regular ICD: Holdsthe highest share in the market due to the increasing occurrences and growing incidence rates of autoimmune diseases.
  • Cardiac Resynchronization Therapy Defibrillators (CRT-D): Holds the second-largest share in the market and is expected to grow at a moderate rate during the forecast period. The growth is mainly due to increasing cardiac arrests among patients, R&D by major players, and strategic partnerships
  • Subcutaneous-ICD (S-ICD): Holds the third-largest share in the market and is expected to grow at a steady rate in the market during the forecast period. New product launches, manufacturing facility expansion in emerging countries such as India, China, Brazil, and other emerging countries could drive the market.
  • Others: Covers accessories and small component parts of implantable cardioverter defibrillators. This segment holds the least share in the market.
By Indication
  • Myocardial Ischemia: Myocardial Ischemia is the largest as well as the fastest-growing segment by indication as ICDs are majorly used in the treatment of myocardial ischemia. Moreover, the prevalence rate of sudden cardiac arrests is rising. Myocardial ischemia is further segmented into symptomatic and asymptomatic.
  • Acute Myocardial Infarction: It is the second-largest segment in the market, and this condition is also commonly called a heart attack. Acute myocardial infarction is a life-threatening condition that occurs when blood flow to the heart muscle is abruptly cut off, causing tissue damage. It is the second-largest segment in the market by indication.
  • Electrolyte Imbalance and Drug Toxicity: It is the third-largest and fastest-growing segment in the market.
By End User
  • Hospitals & Clinics: This is the largest and fastest-growing market segment and is projected to grow well beyond the forecast period. Hospitals and clinics are primary care centers for individuals afflicted with type-1 diabetes and are also cost-effective. Moreover, in countries with government-funded healthcare and a high prevalence of type-1 diabetes, hospitals and clinics are the main treatment centers, which drives the growth of the segment.
  • Ambulatory Surgical Centers: A more specialized treatment option, a large number of specialty centers have established across the US and are being opened in developing nations such as India and China. This segment is growing due to the increased number of individuals afflicted with the condition and the higher returns on investment from specialty centers as compared to hospitals and clinics.
  • Others: The ease of availability and delivery of diabetes medication has led to patients opting for home treatment. The segment also covers old age homes as the geriatric population is highly susceptible to type-1 diabetes. The segment is expected to grow as awareness regarding the condition increases along with the ease of treatment.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICD market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The ICDs market in the Americas is likely to hold a major share owing to the increased patient pool. The European ICD market has been sub-divided classified as Western Europe and Eastern Europe. The Western European market has further been classified categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ICD market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific ICD market is projected to be the fastest-growing due to the increasing incidences of acute myocardial infarction and myocardial infraction, growing aging population, and changing lifestyle (smoking and alcohol consumption) in the region. The ICD market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:

Telehealth Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2024

Market Scenario:
An expert on premium research reports, Market Research provides an in-depth Telehealth Market analysis of regional data with Growth Potential, Opportunities, Drivers, Industry-Specific Challenges
Telehealth or telemedicine is a mode of delivering health care services to patients by using communication technologies to facilitate the diagnosis, treatment, consultation, education care management, and others. Telehealth acts as a bridge to improve the relationship between patient and healthcare providers as well as for improving patient satisfaction & behavioural changes by providing healthcare guidance and treatment. It provides self-management and caregiver’s support to the patients.  Telehealth is used to monitor the chronic diseases as well as to monitor disease from home.
There are tremendous benefits offered by the telehealth solutions. Some of these include improved access to the patients; telehealth can allow us to provide healthcare services to the patients situated in distant locations. It also allows physicians & doctors to expand their reach and services beyond their clinics. Telehealth services have also proved to be cost effective with increased efficiency through better management of chronic diseases. And also it reduces the travel time for the patients which further reduced costs for the patients. All these advantages have attracted healthcare services providers to adopt telehealth technologies and the demand for the same has been on the rise ever since.
The growth of telehealth market size is driven by increasing prevalence of chronic diseases, rising geriatric population, and continuous development in the healthcare technology; as per statistics, more than 50% of the total globe population have some or other chronic disease. Moreover, rapid development in the technology, increasing healthcare expenditure, and increasing need for the home based devices have fuelled the market growth. However, lack of awareness and unavailability or less availability of the required infrastructure in many parts of the world including the underdeveloped Asian and African regions may slow the growth of the market.
The global teleheatlh market is expected to grow at a healthy CAGR of 29.8% during the forecasted period.
Key players
Some of the major players in the global telehealth market are Koninklijke Philips N.V. (the Netherlands), Medtronic (Ireland), General Electric Company (UK), McKesson Corporation (US), Care Innovations, LLC. (US), Cerner Corporation (US), GlobalMedia Group, LLC (US), Siemens Healthcare Private Limited (US), AMD Global Telemedicine, Inc. (US), InTouch Technologies, Inc. (US). 
Segmentation
The global telehealth market is segmented on the basis of components, types, and end users.
On the basis of component, the market is segmented into hardware, software, and others. Hardware is further segmented into monitors, medical devices, and others. Monitors are further segmented into blood glucose monitors, blood pressure monitors, ECG monitors, and others.
On the basis of types, the market is segmented into web based, on-premises, and cloud based. On the basis of end users the market is segmented into hospitals & clinics, pharmaceutical companies, and others. 
Regional Analysis
On the regional basis the global telehealth market is dominated by America owing to the presence of huge geriatric population and large number of people suffering from diabetes and other chronic respiratory diseases. Among all the regions in the world, the U.S. has been the first choice for the deployment of telehealth solutions due to established healthcare systems and technology advancement. It has gained a significant position in the global market with the increase in large numbers of telehealth services which target at wellness and fitness. Thus, these telehealth solutions help in cost reduction, saves time by reducing visits to physicians, and provides better healthcare systems. In Addition to this, well developed healthcare sector and high healthcare spending has contributed in the growth of the market. Europe accounts for the second largest market for the global telehealth market which is followed by Asia Pacific. The Germany is dominating the connected healthcare deployments in Europe, with different kinds of solutions being offered and services being delivered through varied means, from simple messages to much more complex apps. Asia pacific has the fastest growth market due to the presence of rapidly developing economies like China and India. However, the Middle East and Africa has the least share in the market.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/telehealth-market-900  
Posted by at No comments:

Health Insurance Market 2020 Global Dynamics, Trends, Opportunities, Drivers, Challenges and Influence Factors Shared in a Latest Report

Market Scenario:
The Global Health Insurance Market is expected to register a CAGR of ~4.1% during the forecast period of 2019 to 2025 and will achieve USD 141.3 Billion in 2025 with a market value of USD 137.4 billion in 2018.
The increasing participation of key players is one of the key factors driving the health insurance market.
For example, Allianz Partners acquired 100% share capital of Servicios Compartidos Multiasistencia, SL from private equity funds managed by Portobello Capital, and marginal shareholders. Various other factors such as the increase in aging population and rise in health expenditure drive the growth of the market. In addition, rise in per capita disposable incomes of individuals and advancement in R&D in the field of medicine are also expected to propel the growth of the market. However, poor claim settlement track record and rigid rules hinder the market growth. The adoption of social media to create health awareness among the youth and research & development in pharmaceuticals is providing opportunities to increse the global health insurance market trends and size.
Segmentation
The global health insurance market is segmented based on demographics, type, term, service providers, and region.
The global market for health insurance, by demographics, has been divided into minor, adult and senior citizens. Adults aged 18–64, 69.0% (136.7 million) were covered by private health insurance plans in the first 9 months of 2018 in the US.
Based on type, the market has been segmented into health maintenance organizations (HMOs), exclusive provider organizations (EPOs), point-of-service (POS) plans, and preferred provider organizations (PPOs). A health maintenance organization (HMO), is a prepaid health plan. The health maintenance organization (HMO) member pays a monthly premium. In return, the health maintenance organization (HMO) offers wide-ranging health care facilities such as emergency care, hospital stays, surgery, laboratory (lab) tests, X-rays, doctor’s visits, and therapy
Based on the period, the market has been segregated into lifetime coverage and term insurance.  The Patient Protection and Affordable Care Act (PPACA) or Obamacare, abolished lifetime maximum benefit clauses in healthcare policies wherever they relate to essential services. The Affordable Care Act legislation also eliminates the facility for health care insurers to place yearly maximums on essential services such as ambulatory patient services, maternity, pregnancy, and neonatal care, laboratory services, and others.
Based on the service providers, the market has been bifurcated into public and private. The public health insurance has been further sub-categorized as Medicare and Medicaid. The private health insurance has been sub-segmented into primary private health insurance, duplicate private health insurance, complimentary private health insurance, and supplementary private health insurance. The number of Americans registered in private healthcare plans has increased from 12.8% to 34% between 2004 and 2017.
In the current scope of the study, the segments mentioned above are covered across four global regions, namely the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The health insurance market in the Americas has further been segmented into North America and South America, with the North American market has been divided into the US and Canada. The European health insurance market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The health insurance market in Asia-Pacific has been categorized as Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The health insurance market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
  • Allianz SE
  • IHI-Bupa
  • William Russell
  • Aetna
  • Blue Cross
  • Expacare
  • CIGNA
  • International SOS
  • MediCare International
  • Integra Global Health Limited
  • HealthCare International
  • MultiNational Underwriters
Regional Market Summary
The Americas dominated the global market for health insurance owing to the increasing awareness among the people about chronic diseases and many players are coming up with new insurance ideas for the welfare of the individuals. The percentage of people with health insurance coverage for 2017 was 91.2 % in the US. The US continues to be the largest contributor to the complete growth of health premiums worldwide, driven by the expansion of coverage implemented with the Affordable Care Act.
In 2018, it was estimated that Europe stood second in the global health insurance market. Technological advancements, along with the availability of funding opportunities in research and innovation will support the growth of health insurance during the review period. Other factors such as a favorable reimbursement scenario, rise in government expenditure on healthcare, and increase in geriatric population in this region can be attributed to the market growth.
Asia-Pacific (APAC) is expected to witness a phenomenal growth in health insurance throughout the forecast period due to rising participation of market players in launching innovative health insurance policies and the growing demand for the treatment of chronic diseases, lenient regulations, adoption of innovative technologies, and rise in medical tourism. The fastest-growing regional market in APAC, mostly fueled by the efforts of companies in China and India to increase health insurance penetration, with China concentrating on its aging population and India on its rural population. Net profit margins in APAC are also the highest globally, led by smaller regional markets such as Hong Kong and Singapore.
On the other hand, the Middle East & Africa holds the least share in the global health insurance market due to the low economic development, especially within the African region.
Posted by at No comments:

Nasal Drug Delivery Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2023

Market Scenario
The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new nasal drug delivery technology market, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the nasal drug delivery market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Posted by at No comments:

Global Cough Syrup Market 2020 by manufacturers, Demand, application, and region 2023

Market Scenario:
The Global Cough Syrup Market Statistics expects to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Cough syrups are the medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key factors contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with an active pharmaceutical sector, are boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the Cough Syrupmarket size.
Market Dynamics
Rising air pollution is acting as a driver for the growth of the market. Air pollution is a major environment-related health threat that stands as a risk factor for both acute and chronic respiratory diseases. According to a report by the Forum of International Respiratory Societies (FIRS), tobacco smoke, indoor air pollution from burning fuels, and air pollution from traffic and industrial sources are highlighted as the primary contributing factors for most respiratory conditions. World Health Organization (WHO) estimated that 4.3 million deaths per year could be attributed to indoor air pollution. Most diseases and deaths that can be attributed to prolonged exposure to poor indoor air quality occurs primarily in women and children, especially in low-income families. Exposure to indoor smoke used for heating and cooking leads to COPD, lung cancer, and, in children, it causes pneumonia and asthma. This large population affected with respiratory disorders due to air pollution is driving the market for cough syrup market as it is a crucial medicine used for the treatment of such diseases.
Segmentation
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, the market has been segmented into cough suppressants and expectorants. And by application, the cough syrup market has been categorized as adults and children.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region to combat these concerns effectively through the use of cough syrups.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Players
The prominent players in the global cough syrup market are Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France).
The players operating in the global cough syrup market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In February 2019, Merck invested USD 70 million to expand its research & development (R&D) facility in Billerica, Massachusetts for the development of innovative clinical pipeline products.
  • In July 2018, Johnson & Johnson acquired Zarbee's Naturals, a drug-free children's cough syrup. This enabled the company to broaden its product portfolio globally.
  • In December 2016, Pfizer, Inc., launched a series of products as a line extension under the Corex brand name. The first launch was on December 2016, and subsequent launches were conducted in 2017. These formulations were duly approved by central and state regulators.Bottom of Form
Posted by at No comments:
Subscribe to: Posts (Atom)